Ossium Health fetches $63m Series B

Ossium Health, a therapeutics company focused on using stem cell science to improve treatment for patients with blood and immune diseases, has closed $63 million in Series B funding.

ByIris Dorbian

22 March 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Ossium Health fetches $63m Series B

First Round Capital

General Catalyst Partners

Manta Ray Ventures

Vivo Capital

Related articles